India's Glenmark Signs Licensing Deal With Lay Line Genomics
This article was originally published in PharmAsia News
Executive SummaryIndia's Glenmark Pharmaceuticals has signed a licensing agreement with Lay Line Genomics of Italy to promote it's treatments for chronic pain and inflammation
You may also be interested in...
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.